<DOC>
	<DOCNO>NCT02053896</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy ISU302 patient Type 1 Gaucher disease previously treat Imiglucerase .</brief_summary>
	<brief_title>A Switch-Over Study Safety Efficacy ISU302 Patients With Type 1 Gaucher Disease</brief_title>
	<detailed_description />
	<mesh_term>Gaucher Disease</mesh_term>
	<criteria>Patient diagnose type1 Gaucher disease Patient stably treat Gaucher disease Cerezyme® maintaining usage dosage Cerezyme® least 6 month prior study drug administration Patient age 2 year higher Female patient contraception study period ( oral injectable contraceptive hormone , intrauterine device , physical device use condom , sponge form , jelly , femidom , abstinence ) Patient sign informed consent form hearing detailed explanation study Definition stable treatment type1 Gaucher disease : No neurologic deficit Normal hemoglobin concentration , platelet count increase ≥100,000/㎣ , maintain 100,000/㎣ Normal deteriorate bone mineral density Normal deteriorate splenomegaly hepatomegaly Patient participate clinical study within 90 day study drug administration Patient unstable hemoglobin platelet count least 6 month study drug administration Patient hypersensitivity Cerezyme® Patient positive HIV antibody , hepatitis B antigen , hepatitis C antibody Patient Fe , folic acid , vitamin B12deficcient anemia Patient receive miglustat within 6 month study drug administration Patient receive erythrocyte growth factor chronic systemic corticosteroid within 6 month study drug administration Patient clinically significant splenic obstruction within 12 month study drug administration Pregnant lactate patient Patient serious concurrent diseases infectious disease drugaddicted patient Patient consider inappropriate study investigator subinvestigators</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Type I Gaucher</keyword>
	<keyword>ISU302</keyword>
	<keyword>Imiglucerase</keyword>
</DOC>